Drug repurposing for cancer therapy

Journal of Cancer Science and Therapy

Volumn 4, Issue 7, 2012, Pages

  Telleria, Carlos M ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Cancer therapy; Drug repositioning; Drug repurposing

Indexed keywords

GESTAGEN; GLUCOCORTICOID RECEPTOR ANTAGONIST; IMATINIB; METFORMIN; MIFEPRISTONE; PLATINUM; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CUSHING SYNDROME; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG REPURPOSING; DRUG SAFETY; EDITORIAL; EMERGENCY CONTRACEPTION; ENDOMETRIOSIS; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HUMAN; HYPERGLYCEMIA; MENSTRUATION; MORNING SICKNESS; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL CONTRACEPTION; PREGNANCY TERMINATION; TERATOGENICITY; UTERUS MYOMA;

EID: 84866140242     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000e108     Document Type: Editorial

References (39)

1. Gagne D, Pons M, Philibert D (1985) RU 38486: a potent antiglucocorticoid in vitro and in vivo. J Steroid Biochem 23: 247-251.
2. Baulieu EE, Ulmann A, Philibert D (1987) Contragestion by antiprogestin RU 486: a review. Arch Gynecol Obstet 241: 73-85.
3. Bosc MJ, Germain G, Nicolle A, Mouren M, Philibert D, et al. (1987) Control of birth in rats by RU 486, an antiprogesterone compound. J Reprod Fertil 79: 1-8.
4. Ulmann A, Dubois C, Philibert D (1987) Fertility control with RU 486. Horm Res 28: 274-278.
5. Rauch M, Loosfelt H, Philibert D, Milgrom E (1985) Mechanism of action of an antiprogesterone, RU486, in the rabbit endometrium. Effects of RU486 on the progesterone receptor and on the expression of the uteroglobin gene. Eur J Biochem 148: 213-218.
6. Historical Information on Mifepristone (marketed as Mifeprex).
7. FDA approves Korlym for patients with endogenous Cushing's syndrome.
8. Carley DW (2005) Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part II. IDrugs 8: 310-313.
9. Carley DW (2005) Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I. IDrugs 8: 306-309.
10. Weir SJ, DeGennaro LJ, Austin CP (2012) Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res 72: 1055-1058.
11. Benagiano G, Bastianelli C, Farris M (2008) Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. Expert Opin Pharmacother 9: 2487-2496.
12. Benagiano G, Bastianelli C, Farris M (2008) Selective progesterone receptor modulators 2: use in reproductive medicine. Expert Opin Pharmacother 9: 2473-2485.
13. Moller C, Hoffmann J, Kirkland TA, Schwede W (2008) Investigational developments for the treatment of progesterone-dependent diseases. Expert Opin Investig Drugs 17: 469-479.
14. Goyeneche AA, Caron RW, Telleria CM (2007) Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res 13: 3370-3379.
15. Freeburg EM, Goyeneche AA, Seidel EE, Telleria CM (2009) Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity. Cancer Cell Int 9: 4.
16. Freeburg EM, Goyeneche AA, Telleria CM (2009) Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Int J Oncol 34: 743-755.
17. Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT, Telleria CM (2011) Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer 11: 207.
18. Goyeneche AA, Seidel EE, Telleria CM (2012) Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2. Invest New Drugs 30: 967-980.
19. Telleria CM, Goyeneche AA (2012) Antiprogestins in Ovarian Cancer. Ovarian Cancer-Clinical and Therapeutic Perspectives; Samir Farghaly (Eds).
20. Kaiser J (2011) Biomedicine. NIH's secondhand shop for tried-and-tested drugs. Science 332: 1492.
21. Song CW, Lee H, Dings RP, Williams B, Powers J, et al. (2012) Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep 2: 362.
22. Breitkreutz I, Anderson KC (2008) Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 4: 973-985.
23. Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, et al. (2008) A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 34: 442-452.
24. Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, et al. (2008) Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111: 3968-3977.
25. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4: 314-322.
26. Fletcher I (1980) Review of the treatment of thalidomide children with limb defeciency in Great Britain. Clin Orthop Relat Res (148): 18-25.
27. Knobloch J, Ruther U (2008) Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle 7: 1121-1127.
28. Nadal E, Olavarria E (2004) Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies. Int J Clin Pract 58: 511-516.
29. Nimmanapalli R, Bhalla K (2002) Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias. Curr Opin Oncol 14: 616-620.
30. Melo JV, Chuah C (2007) Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 249: 121-132.
31. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, et al. (2006) Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 24: 727-733.
32. Collins FS (2011) Reengineering translational science: the time is right. Sci Transl Med 3: 90cm17.
33. Discovering new therapeutic uses for existing molecules. National Center for Advancing Translational Sciences.
34. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE (2007) Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 166: 894-901.
35. Vessey M, Painter R (2006) Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 95: 385-389.
36. Rosenberg B, VanCamp L (1970) The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res 30: 1799-1802.
37. Rosenberg B, VanCamp L, Trosko JE, Mansour VH (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222: 385-386.
38. Rosenberg B, Van Camp L, Grimley EB, Thomson AJ (1967) The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (IV) complexes. J Biol Chem 242: 1347-1352.
39. Rosenberg B, Vancamp L, Krigas T (1965) Inhibition of Cell Division in Escherichia Coli by Electrolysis Products from a Platinum Electrode. Nature 205: 698-699.